Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
Following completion of at least 1 week of study drug for all subjects in group 1, the Sponsor will review the safety information of these subjects prior to enrolling off-treatment subjects into the next dose group. Dose escalation will continue in this manner (unless stopping criteria are met) until all groups have completed the study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has moderate to severe plaque psoriasis for 6 months or longer with at least 10% Body Surface Area (BSA) affected
Subject must be a candidate for phototherapy and/or systemic therapy
You may not be if
Subject has non-plaque psoriasis or drug-induced psoriasis
Subject is on systemic psoriasis therapy within 56 days or 5 half-lives, whichever is longer, prior to first dose of study drug
Subject has a positive TB skin test within 3 months of screening or at screening
